论文部分内容阅读
目的：探究重组人干扰素-γ与泼尼松联用治疗特发性肺间质纤维化的应用价值。方法选取从2012年1月至2015年1月在我院进行治疗的特发性肺间质纤维化患者120例,随机分为两组,观察组60例患者进行重组人干扰素-γ与泼尼松治疗,对照组60例患者进行泼尼松治疗,对2组患者治疗效果进行对比分析。结果观察组患者刺激性干咳好转38例(63．3%),呼吸困难好转34例(56．7%),活动能力好转36例(60．0%),肺弥散功能好转34例(56．7%)；对照组患者刺激性干咳好转20例(33．3%),呼吸困难好转16例(26．7%),活动能力好转12例(20．0%),肺弥散功能好转12例(20．0%),差异有统计学意义(P<0．05)。治疗后,两组患者血清纤维化指标均得到了不同程度改善,观察组患者Ⅲ型胶原蛋白为(51．0±11．5) ng/L,Ⅳ型胶原蛋白为(63．1±21．6) ng/L,透明质酸为(78．6±31．6) ng/L；对照组患者Ⅲ型胶原蛋白为(80．5±17．2) ng/L,Ⅳ型胶原蛋白为(70．3±24．5) ng/L,透明质酸为(87．8±26．7) ng/L。与治疗前相比差异有统计学意义(P<0．05),治疗后两组患者相比差异有统计学意义(P<0．05)。结论在进行特发性肺间质纤维化治疗时,重组人干扰素-γ与泼尼松治疗联用的方法效果良好,能够减轻患者病症,应在临床中推广使用。“,”Objective To explore the efficacy of recombinant human interferon-γ and prednisone in the treatment of patients with idiopathic pulmonary fibrosis. Methods 120 patients with idiopathic pulmonary fibrosis from January 2012 to January 2015 were randomly divided into 2 groups. The observation group was treated with re-combinant human interferon-γand prednisone, and the control group was treated with prednisone. The curative effect was analyzed and compared between the two groups. Results In the observation group, there were 38 cases of stimula-ting dry cough improved (63. 3%), and 34cases of dyspnea improved (56. 7%), 36 cases of activity improved (60. 0%) and 34 cases of lung diffusion function improved (56. 7%). In the control group, there were 20 cases of irritating cough improved ( 33. 3%) , 16 cases of dyspnea improved ( 26. 7%) , 12 cases of activity improved (20. 0%), and 12 cases of pulmonary diffusion function improved (20. 0%) (P<0. 05). After the treatment, the indexes of serum fibrosis all improved, and the improvement was more pronounced in the observation group than in the control group (P<0. 05). The level of typeⅢ collagen was (51 ± 11. 5) ng/L, typeⅣ collagen was (63. 1 ± 21. 6) ng/L, and hyaluronic acid was (78. 6 ± 31. 6) ng/L in the observation group. The level of type Ⅲ collagen was (80. 5 ± 17. 2) ng/L, type Ⅳ collagen was (70. 3 ± 24. 5) ng/L, and hyaluronic acid was (87. 8 ± 26. 7) ng/L. Conclusion In the treatment of idiopathic pulmonary fibrosis, recombinant human interferon-γ and prednisone have a good curative effect, which can relieve patients’ pathological symptom and should be promoted in clinical use.